These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092 [TBL] [Abstract][Full Text] [Related]
4. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease. Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803 [TBL] [Abstract][Full Text] [Related]
14. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274 [TBL] [Abstract][Full Text] [Related]
15. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235 [TBL] [Abstract][Full Text] [Related]
16. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows. Xicoy H; Peñuelas N; Vila M; Laguna A Cells; 2019 Oct; 8(11):. PubMed ID: 31731485 [TBL] [Abstract][Full Text] [Related]
17. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Wong YC; Krainc D Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775 [TBL] [Abstract][Full Text] [Related]
18. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Xilouri M; Brekk OR; Stefanis L Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776 [TBL] [Abstract][Full Text] [Related]
19. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Huebecker M; Moloney EB; van der Spoel AC; Priestman DA; Isacson O; Hallett PJ; Platt FM Mol Neurodegener; 2019 Nov; 14(1):40. PubMed ID: 31703585 [TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of the Lysosome in Parkinson's Disease. Navarro-Romero A; Montpeyó M; Martinez-Vicente M Cells; 2020 Nov; 9(11):. PubMed ID: 33147750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]